Liver Cancer: Declining Incidence, Persistent Mortality | Market Intelligence

Description

List of Tables

Liver cancer in Japan is a study in contradiction. The country engineered one of the world's most successful viral-hepatitis control stories, and hepatocellular carcinoma incidence has been falling for years as the HCV-infected cohort ages out. Yet liver cancer remains a stubborn cause of cancer death, still ranking high among male cancer mortality, because the disease presents late, recurs often, and now arises increasingly from metabolic liver disease rather than from a virus that medicine has largely learned to suppress. For oncology and hepatology stakeholders, the question is no longer whether Japan can control viral liver cancer - it is what replaces that fight.

The tension runs through every layer of the system. Surveillance of high-risk patients through ultrasound and tumor markers is entrenched in guideline practice but unevenly delivered outside specialist centers. Treatment has been transformed by immunotherapy combinations - Tecentriq plus Avastin, the Opdivo plus Yervoy first-line approval in 2025, and the Japan-originated Lenvima franchise that anchored systemic therapy for years - yet real-world sequencing, tolerability in an elderly cirrhotic population, and the role of locoregional therapy alongside systemic drugs remain contested. At the same time, the metabolic-disease pipeline of future patients grows as MASLD and MASH prevalence rises with little organized screening.

This report maps the full liver cancer landscape in Japan. It opens with the epidemiological transition from viral to metabolic etiology and the surveillance infrastructure built around high-risk cohorts. Treatment chapters cover resection, ablation, transarterial therapies, and the systemic therapy landscape line by line, including the positioning of each immunotherapy combination and Japan's own Lenvima heritage. Dedicated analysis addresses how a declining-incidence market changes commercial logic, how liver transplant policy constrains one curative route, and how the system compares with the United States, Europe, and China.

The report is written for oncology business-development teams weighing Japan investment in a shrinking-but-complex indication, hepatology networks planning service configuration, and investors assessing franchise durability for the companies active in Japanese liver cancer care.

Scope and Coverage: The report covers hepatocellular carcinoma and intrahepatic cholangiocarcinoma in Japan across etiology, surveillance, diagnosis, locoregional treatment, and systemic therapy. Comparative chapters reference the United States, Europe, and China on surveillance design and drug access.

Report Highlights:

The HCV-to-MASH etiological transition and its implications for surveillance target populations
Ultrasound and tumor-marker surveillance program structure and adherence patterns
Locoregional therapy practice: resection, ablation, and transarterial treatment pathways
Systemic therapy landscape including Lenvima, Tecentriq-Avastin, and Opdivo-Yervoy positioning
Japan's liver transplant policy and its effect on curative-treatment options
Franchise and competitive analysis for the companies active in Japanese liver cancer care

Product Code: JPH-040

Table of Content

1. Executive Summary

2. Liver Cancer: Overview and Clinical Background

3. Epidemiology and Patient Population: US, EU5, Japan, and China

4. Current Treatment Landscape and Standard of Care

5. Pipeline and Development Activity

6. Regulatory Pathways: FDA, EMA, PMDA, and NMPA Considerations

7. Reimbursement and Pricing Analysis with a Focus on Japan's NHI System

8. Competitive Landscape and Key Companies

9. Unmet Needs and Commercial Opportunities in Japan

10. Appendix: Methodology and Sources

Companies Mentioned

Bristol Myers Squibb (US) - Opdivo+Yervoy first-line HCC combination approved in Japan (2025). Ono Pharmaceutical (JP) - Japan marketing rights holder for Opdivo and Yervoy. Roche (CH) - Tecentriq+Avastin first-line HCC backbone from IMbrave150. Chugai (JP) - Japan commercialization of Tecentriq and Avastin. Eisai (JP) - Lenvima (lenvatinib), Japan-originated first-line HCC standard from REFLECT. AstraZeneca (UK) - Imfinzi+Imjudo STRIDE regimen from HIMALAYA in first-line HCC. BeiGene (CN) - tislelizumab HCC indications from RATIONALE programs. Hengrui (CN) - camrelizumab+rivoceranib combination from CARES-310. Merck & Co (US) - Keytruda in later-line HCC. Eli Lilly (US) - Cyramza (ramucirumab) for AFP-elevated HCC. Fujifilm Wako (JP) - μTASWako AFP-L and PIVKA-II surveillance biomarkers. Sysmex (JP) - HISCL AFP and PIVKA-II testing plus liquid-biopsy development in HCC. Bayer (DE) - Nexavar legacy first-line standard and Stivarga in later lines. Exelixis (US) - Cabometyx (cabozantinib) in later-line HCC, licensed to Takeda in Japan.

Product Code: JPH-040

List of Tables

Table 1. Liver cancer incidence and mortality statistics in Japan by sex and age band
Table 2. Hepatocellular carcinoma versus intrahepatic cholangiocarcinoma case distribution
Table 3. HCV-attributable hepatocellular carcinoma trend following DAA treatment expansion
Table 4. HBV-attributable liver cancer burden and vaccination cohort effects in Japan
Table 5. MASLD/MASH-attributable hepatocellular carcinoma trend in Japan
Table 6. Alcohol-related liver disease and liver cancer contribution in Japan
Table 7. Prefectural variation in liver cancer mortality
Table 8. Historical HCV infection cohort structure and aging profile in Japan
Table 9. DAA treatment uptake and HCV elimination program milestones in Japan
Table 10. National liver cancer surveillance recommendations for high-risk groups
Table 11. Ultrasound surveillance practice patterns across facility types
Table 12. AFP, AFP-L3, and DCP tumor-marker testing protocols in Japanese surveillance
Table 13. Surveillance adherence among chronic hepatitis and cirrhosis patients
Table 14. Gd-EOB-DTPA MRI and CT diagnostic pathways for hepatocellular carcinoma
Table 15. Liver biopsy practice and non-invasive fibrosis assessment in Japan
Table 16. Barcelona Clinic Liver Cancer staging application in Japanese practice
Table 17. Japan Society of Hepatology guideline structure and treatment algorithm
Table 18. Hepatectomy practice: volume thresholds and center distribution
Table 19. Radiofrequency and microwave ablation practice for early HCC in Japan
Table 20. Transarterial chemoembolization techniques used in Japanese centers
Table 21. Drug-eluting bead and balloon-occluded TACE adoption
Table 22. Transarterial radioembolization and external-beam radiotherapy status in Japan
Table 23. Living-donor versus deceased-donor liver transplantation policy and volumes
Table 24. Lenvima first-line positioning and Japanese post-marketing evidence base
Table 25. Tecentriq plus Avastin first-line use and bleeding-risk management in Japan
Table 26. Opdivo plus Yervoy first-line HCC approval in Japan (2025) and label scope
Table 27. Durvalumab plus tremelimumab availability and positioning in Japan
Table 28. Second-line and later-line systemic therapy sequencing in Japanese practice
Table 29. Lenvima-Japan heritage: REFLECT trial design and domestic development history
Table 30. Immune-related adverse event management protocols in cirrhotic patients
Table 31. Hepatic arterial infusion chemotherapy practice unique to Japan
Table 32. Conversion surgery strategies after systemic therapy response
Table 33. Intrahepatic cholangiocarcinoma systemic therapy landscape in Japan
Table 34. FGFR2 and IDH1 targeted therapy development status for cholangiocarcinoma in Japan
Table 35. Biomarker testing infrastructure for biliary tract cancer in Japan
Table 36. Pediatric and young-adult liver cancer program structure
Table 37. Liver cancer clinical trial site network in Japan
Table 38. Comparison of first-line HCC treatment access: Japan, US, EU5, China
Table 39. China HCC treatment landscape and domestic PD-1 inhibitor competition
Table 40. NHI reimbursement structure for HCC systemic therapies
Table 41. Drug pricing and repricing exposure of HCC franchises in Japan
Table 42. Supportive care and palliative pathways for advanced liver cancer
Table 43. Nutritional and sarcopenia management in cirrhotic HCC patients
Table 44. Company profiles: Eisai and the Lenvima franchise in Japan
Table 45. Company profiles: Ono and Bristol Myers Squibb immunotherapy positioning
Table 46. Company profiles: Roche/Chugai and the Tecentriq-Avastin program
Table 47. Surveillance economics: cost structure of high-risk cohort follow-up
Table 48. MASH drug pipeline implications for future liver cancer prevention in Japan
Table 49. Research agenda for early detection of liver cancer in metabolic-disease populations
Table 50. Hepatitis B and C screening program coverage and testing guidelines in Japan

List of Figures

Figure 1. Liver cancer incidence trend in Japan by sex, historical series
Figure 2. Liver cancer mortality trend in Japan by sex, historical series
Figure 3. Etiology distribution of hepatocellular carcinoma in Japan over time
Figure 4. HCV cohort aging curve and projected incident-case contribution
Figure 5. DAA treatment uptake trend in Japan
Figure 6. MASH prevalence trend and at-risk population structure
Figure 7. Surveillance pathway for high-risk chronic liver disease patients
Figure 8. Tumor-marker and ultrasound surveillance schedule in Japanese guidelines
Figure 9. Surveillance adherence rates by facility type and region
Figure 10. Diagnostic imaging algorithm for liver nodules in Japan
Figure 11. BCLC stage distribution of newly diagnosed HCC in Japan
Figure 12. Treatment allocation map by stage under Japanese guidelines
Figure 13. Hepatectomy and ablation volume distribution across facility tiers
Figure 14. TACE technique mix across Japanese centers
Figure 15. Liver transplantation volume trend in Japan
Figure 16. First-line systemic therapy positioning map in Japan
Figure 17. Timeline of HCC systemic therapy approvals in Japan
Figure 18. Lenvima, atezolizumab-bevacizumab, and nivolumab-ipilimumab treatment flow
Figure 19. Second-line sequencing pathways after first-line immunotherapy
Figure 20. Hepatic arterial infusion chemotherapy workflow in Japanese practice
Figure 21. Conversion surgery pathway after systemic therapy
Figure 22. Immune-related adverse event management flow in cirrhotic patients
Figure 23. Intrahepatic cholangiocarcinoma treatment algorithm in Japan
Figure 24. Biomarker testing cascade for biliary tract cancer
Figure 25. Clinical trial enrollment geography for HCC studies in Japan
Figure 26. First-line HCC access comparison: Japan, US, EU5, China
Figure 27. China domestic PD-1 inhibitor landscape in HCC
Figure 28. NHI price trajectory of major HCC franchises in Japan
Figure 29. Repricing events affecting HCC systemic therapies
Figure 30. Surveillance cost structure for high-risk cohorts
Figure 31. Facility-level liver cancer care pathway from primary to tertiary centers
Figure 32. Regional disparity map in liver cancer outcomes within Japan
Figure 33. Five-year survival by stage for HCC in Japan versus international benchmarks
Figure 34. Palliative care integration timing in advanced liver cancer
Figure 35. Nutritional intervention pathways in cirrhotic HCC care
Figure 36. MASH therapeutic pipeline and overlap with hepatology practice
Figure 37. Company positioning map across the Japanese HCC care pathway
Figure 38. Eisai Lenvima lifecycle strategy schematic
Figure 39. Roche/Chugai and Ono/BMS competitive positioning in first-line HCC
Figure 40. Referral flows between hepatology and oncology services in Japan
Figure 41. HCC surveillance recall systems and reminder program models
Figure 42. Early-detection biomarker research pipeline for liver cancer in Japan
Figure 43. Liquid biopsy research activity in Japanese liver cancer cohorts
Figure 44. Multidisciplinary conference structure for liver cancer in designated hospitals
Figure 45. Child-Pugh distribution of systemic-therapy candidates in real-world practice
Figure 46. Locoregional-systemic combination trial designs active in Japan
Figure 47. HBV vaccination and screening program coverage in Japan
Figure 48. Alcohol-related liver disease care pathway and cancer risk management
Figure 49. Research agenda for surveillance modernization in the post-HCV era
Figure 50. Japan Society of Hepatology guideline update cycle and evidence structure

Liver Cancer: Declining Incidence, Persistent Mortality | Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Liver Cancer: Overview and Clinical Background

3. Epidemiology and Patient Population: US, EU5, Japan, and China

4. Current Treatment Landscape and Standard of Care

5. Pipeline and Development Activity

6. Regulatory Pathways: FDA, EMA, PMDA, and NMPA Considerations

7. Reimbursement and Pricing Analysis with a Focus on Japan's NHI System

8. Competitive Landscape and Key Companies

9. Unmet Needs and Commercial Opportunities in Japan

10. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures